Drug change from nintedanib to pirfenidone for the perioperative management of lung cancer with idiopathic pulmonary fibrosis: A case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug change from nintedanib to pirfenidone for the perioperative management of lung cancer with idiopathic pulmonary fibrosis: A case report

Published:2024-07-15 Issue:5 Volume:38 Page:446-452
ISSN:0919-0945
Container-title:The Journal of the Japanese Association for Chest Surgery
language:en
Short-container-title:Jpn J Chest Surg

Author:

Matsui Yukiko¹²,Abe Mitsuhiro³,Uematsu Yasufumi¹²,Onozato Yuki¹⁴,Yamamoto Takayoshi¹,Iwata Takekazu¹

Affiliation:

1. Division of Thoracic Surgery, Chiba Cancer Center

2. Department of General Thoracic Surgery, Chiba University Graduate School of Medicine

3. Department of Respiratory Medicine, Chiba University Hospital

4. Department of Thoracic Surgery, International University of Health and Welfare School of Medicine

Publisher

Japanese Association for Chest Surgery

Link

https://www.jstage.jst.go.jp/article/jacsurg/38/5/38_446/_pdf

Reference21 articles.

1. 1. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.

2. 2. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.

3. 3. Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res 2019; 20: 205.

4. 4. Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, et al. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res 2020; 21: 196.

5. 5. Omori T, Tajiri M, Baba T, Ogura T, Iwasawa T, Okudela K, et al. Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg 2015; 100: 954-60.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3